Evaluation of a new ultrashort triple therapy for Helicobacter pylori disease

Autor:	M. Caselli, Lucio Trevisani, F. Galvani, G. Verdianelli, V. Abbasciano, M. Ruina, S. Sartori
Rok vydání:	1998
Předmět:	medicine.medical_specialty Hepatology biology business.industry medicine.drug_class Gastroenterology Lansoprazole Rapid urease test Proton-pump inhibitor Helicobacter pylori biology.organism_classification Azithromycin Tinidazole Surgery Tolerability Internal medicine Medicine Pharmacology (medical) business medicine.drug Antibacterial agent
Zdroj:	Alimentary Pharmacology & Therapeutics. 12:1269-1272
ISSN:	0269-2813
DOI:	10.1046/j.1365-2036.1998.00430.x
Popis:	Background: 1-week proton pump inhibitor-based triple therapies are considered the most effective and convenient drug combinations for curing Helicobacter pylori infection. Short therapies, lasting less than 1 week have been investigated rarely. Aim: To assess the efficacy and tolerability of a 3-day lansoprazole triple therapy after 1 day of lansoprazole pre-treatment. Methods: Seventy H. pylori-positive (rapid urease test and histology) patients received LAzT3 regimen (lanzoprazole 30 mg b.d. and azithromycin 500 mg o.m. for 3 days; tinidazole 2000 mg o.m. on day 1 and 1000 mg o.m. on days 2–3) after 1 day of lansoprazole pre-treatment. Patients with active ulcer received lansoprazole 30 mg o.m. for an additional 4 weeks. Follow-up gastroscopy was carried out 4–6 weeks after completion of therapy. Eradication was defined as negative histology and rapid urease test. Results: Four patients failed to attend the follow-up endoscopy. One patient complained of minor side-effects. H. pylori was eradicated in 57 of 66 patients suitable for evaluation, with a per-protocol cure rate of 86.3% (95%CI: 76–94%), and an intention-to-treat cure rate of 81.4% (95%CI: 70–90%). Conclusions: This new ultrashort triple therapy including lansoprazole, azithromycin and tinidazole seems to be effective in eradicating H. pylori. It is safe and well-tolerated, and may be taken into consideration as a valid alternative to the better known and widely used 1-week proton pump inhibitor-based triple therapies.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::7d4e06b682297c95865b576ef138ed0b https://doi.org/10.1046/j.1365-2036.1998.00430.x Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.